Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Piper Jaffray Sees FDA Approving Inspire Pharmaceuticals Drug

Piper Jaffray says Inspire Pharmaceuticals (ISPH) has a good chance for Food and Drug Administration approval of its new drug Diquafosol.

Analyst Mark Karvosky sees stock price upside of $8 to $9 (he has a $16 target) if the biopharmaceutical company receives Food and Drug Administration approval with downside of $1 to $2 if the company is required to do additional trials. He says his clinical contacts continue to confirm that diquafosol's ability to clear the central region of the cornea is clinically meaningful. Still, he notes that the FDA may ask Inspire to complete an additional trial with central corneal clearing as its primary endpoint. He continues to rate the stock at outperform.

blog comments powered by Disqus